HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis



Document title: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Journal: Sao Paulo medical journal
Database: PERIÓDICA
System number: 000380068
ISSN: 1516-3180
Authors:





Year:
Season: Sep
Volumen: 132
Number: 5
Pages: 314-315
Country: Brasil
Language: Inglés
Document type: Revisión bibliográfica
Approach: Analítico
English abstract Cardiovascular disease (CVD) is the most frequent cause of death in people with early stages of chronic kidney disease (CKD), for whom the absolute risk of cardiovascular events is similar to people who have existing coronary artery disease. This is an update of a review published in 2009, and includes evidence from 27 new studies (25,068 participants) in addition to the 26 studies (20,324 participants) assessed previously; and excludes three previously included studies (107 participants). This updated review includes 50 studies (45,285 participants); of these 38 (37,274 participants) were meta-analysed. OBJECTIVE: To evaluate the benefits (such as reductions in all-cause and cardiovascular mortality, major cardiovascular events, MI and stroke; and slow progression of CKD to end-stage kidney disease (ESKD)) and harms (muscle and liver dysfunction, withdrawal, and cancer) of statins compared with placebo, no treatment, standard care or another statin in adults with CKD who were not on dialysis. METHODS: Search methods: We searched the Cochrane Renal Group's Specialised Register to 5 June 2012 through contact with the Trials' Search Co-ordinator using search terms relevant to this review. Selection criteria: Randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of statins with placebo, no treatment, standard care, or other statins, on mortality, cardiovascular events, kidney function, toxicity, and lipid levels in adults with CKD not on dialysis were the focus of our literature searches. Data collection and analysis: Two or more authors independently extracted data and assessed study risk of bias. Treatment effects were expressed as mean difference (MD) for continuous outcomes (lipids, creatinine clearance and proteinuria) and risk ratio (RR) for dichotomous outcomes (major cardiovascular events, all-cause mortality, cardiovascular mortality, fatal or non-fatal myocardial infarction (MI), fatal..
Disciplines: Medicina
Keyword: Farmacología,
Nefrología,
Sistema cardiovascular,
Estatinas,
Insuficiencia renal crónica (IRC),
Ensayos clínicos,
Colaboración Cochrane,
Enfermedades cardiovasculares
Keyword: Medicine,
Cardiovascular system,
Nephrology,
Pharmacology,
Statins,
Chronic renal failure (CRF),
Clinical assays,
Cochrane collaboration,
Cardiovascular diseases
Full text: Texto completo (Ver HTML)